IL325890A - מודולטור של קולטן לאדנוזין a2a ו-a2b - Google Patents

מודולטור של קולטן לאדנוזין a2a ו-a2b

Info

Publication number
IL325890A
IL325890A IL325890A IL32589026A IL325890A IL 325890 A IL325890 A IL 325890A IL 325890 A IL325890 A IL 325890A IL 32589026 A IL32589026 A IL 32589026A IL 325890 A IL325890 A IL 325890A
Authority
IL
Israel
Prior art keywords
adenosine
modulators
receptor
Prior art date
Application number
IL325890A
Other languages
English (en)
Original Assignee
Ryvu Therapeutics S A
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryvu Therapeutics S A, BioNTech SE filed Critical Ryvu Therapeutics S A
Publication of IL325890A publication Critical patent/IL325890A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL325890A 2023-07-17 2023-07-17 מודולטור של קולטן לאדנוזין a2a ו-a2b IL325890A (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PL2023/050060 WO2025018901A1 (en) 2023-07-17 2023-07-17 Modulators of the adenosine a2a and a2b receptor

Publications (1)

Publication Number Publication Date
IL325890A true IL325890A (he) 2026-03-01

Family

ID=87696037

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325890A IL325890A (he) 2023-07-17 2023-07-17 מודולטור של קולטן לאדנוזין a2a ו-a2b

Country Status (4)

Country Link
CN (1) CN121532395A (he)
AU (1) AU2023454063A1 (he)
IL (1) IL325890A (he)
WO (1) WO2025018901A1 (he)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058241A2 (en) 2000-02-10 2001-08-16 New York University Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
JP2005123160A (ja) 2003-09-22 2005-05-12 Nissan Motor Co Ltd 燃料電池用セパレータ、燃料電池スタック及び燃料電池用セパレータの製造方法並びに燃料電池車両
CN101060841A (zh) 2004-06-17 2007-10-24 加利福尼亚大学董事会 拮抗腺苷a2a受体来改善成瘾行为的一种或多种构成
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
US20200369665A1 (en) 2017-06-30 2020-11-26 Ryvu Therapeutics S.A. Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor
WO2020128036A1 (en) 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor

Also Published As

Publication number Publication date
AU2023454063A1 (en) 2026-01-15
WO2025018901A1 (en) 2025-01-23
CN121532395A (zh) 2026-02-13

Similar Documents

Publication Publication Date Title
GB2609879B (en) Antagonists of the adenosine A2a receptor
AU2022246176A1 (en) Adenosine deaminase variants and uses thereof
IL276873A (he) מידאזופירימידינים וטריאזולופירימידינים כמעכבי a2a /a2b
IL270909A (he) מודולטורים מסוג אימידאזו[a–1,2]פיראזין לקולטן אדנוסין a2a
IL277160A (he) תכשירים רפואיים נוקלאוטידיים ונוקלאוזידיים המכילים '4-הלוגן ושימושים הקשורים אליהם
EP4141007A4 (en) ANTIVIRAL USE OF A NUCLEOSIDE ANALOGUE OR A COMBINATION FORMULATION CONTAINING A NUCLEOSIDE ANALOGUE
IL279562A (he) נוקלאודיטים ונוקלאוסידים בעלי קבוצות חסימה '3-הידרוכסי
EP4185296A4 (en) DUAL ADENOSINE A2A RECEPTOR AND A2B RECEPTOR ANTAGONISTS FOR IMMUNO-ONCOLOGY
ZA200703229B (en) Use of A2A adenosine receptor agonists
HUE066718T2 (hu) Pirazolopiridinek és triazolopiridinek mint A2A/A2B inhibitorok
EP4040965A4 (en) THERAPEUTIC COMPOSITIONS BASED ON NUCLEOSIDES AND NUCLEOTIDES CONTAINING 4-HALOGEN AND ASSOCIATED USES
GB202217705D0 (en) Multi-seat escape system and ejection seat sequencer
IL311972A (he) מבני ציטוקין הניתנים להפעלה ושיטות צירוף
CA3295477A1 (en) Modulators of the adenosine a2a and a2b receptor
EP4234566A4 (en) MODIFIED NUCLEOSIDE OR NUCLEOTIDE
EP4192916A4 (en) COMBINATION THERAPY WITH ADENOSINE RECEPTOR ANTAGONISTS
IL307967A (he) פורין נוקליאוזידים, חומרי ביניים שלהם ושיטות להכנתם
PL3833756T3 (pl) Enzymy epimerazy i ich zastosowanie
HK40081026A (en) Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
HK40089682A (en) Antagonists of the adenosine a2a receptor
EP4108670A4 (en) BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING IT
HK40065313A (en) Adenosine a2a receptor antagonists and uses thereof
HK40106784A (en) Adenosine deaminase variants and uses thereof
IL287417A (he) נגזרות ציטידין ושיטות להכנת נגזרות ציטידין
HK40045143A (en) Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists